Impact of pre-transplant depth of response on outcomes in patients with multiple myeloma: A report on behalf of Pakistan blood and marrow transplant group

Document Type

Article

Department

Pathology and Laboratory Medicine; Radiation Oncology

Abstract

Background: Depth of response prior to autologous stem cell transplantation (ASCT) has been associated with improved progression-free survival (PFS) in multiple myeloma (MM). This study aimed to evaluate the impact of pre-transplant response depth on post-transplant outcomes in patients with multiple myeloma.
Subjects and methods: This retrospective multicenter analysis, conducted by the Pakistan Blood and Marrow Transplant group, included 223 MM patients treated over 18 years across six centers. Pre-transplant responses were classified using International Myeloma Working Group criteria. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier methods.
Results: The cohort had a mean age of 49 years, with 70.4% males. Back pain (56%) and pathological fractures (15%) were common presenting features. Anemia and renal impairment were noted in 45% and 26%, respectively. The predominant paraprotein subtype was IgG kappa (31%). ISS staging revealed that 33.3% of patients had stage I, 27.4% stage II, and 37.6% stage III disease. Induction therapy included RVd in 42% and CyBorD in 41% of patients. Post-induction responses showed complete stringent response (sCR) in 7.4%, complete response (CR) in 22%, very good partial response (VGPR) in 19%, and partial response (PR) in 18%. Age less than 50 years, favorable induction response, and achieving VGPR or more before ASCT were significantly associated with improved outcomes. At the time of transplant, 58.3% had sCR/CR and 20.2% had VGPR. Median OS was 72.4% at a median of 72 months, while DFS was 57% at a median of 47 months. Patients with sCR/CR prior to ASCT had significantly better OS and DFS.
Conclusion: In resource-constrained settings, achieving a deeper response before ASCT is associated with superior survival outcomes in MM. Optimizing induction to attain at least VGPR may enhance the benefit of transplantation.

Comments

Volume,issue and pagination are not provided by author/publisher.

Publication (Name of Journal)

Asia-Pacific Journal of Clinical Oncology

DOI

10.1111/ajco.70104

Link to Full Text

Share

COinS